Drug intelligence / Profile preview

P9-KLH

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides
Administration: Subcutaneous

Overview

P9-KLH is a peptide-based conjugate vaccine designed for active specific immunotherapy against cancers expressing the GD2 ganglioside. It consists of a peptide (P9) that mimics the GD2 ganglioside, covalently linked to Keyhole Limpet Hemocyanin (KLH), a highly immunogenic carrier protein. This conjugation aims to enhance the immune system's recognition of the GD2 mimic, thereby eliciting robust T-cell dependent cellular and humoral immune responses against GD2-expressing tumor cells, which are often poorly immunogenic on their own. It is being investigated for its potential in treating neuroectodermal tumors like neuroblastoma.

Targets

GD2

Beyond the preview

Go deeper on P9-KLH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P9-KLH.

Explore the full profile